LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000051.4:c.6248G>C
ATM
· NP_000042.3:p.(Gly2083Ala)
· NM_000051.4
GRCh37: chr11:108188149 G>C
·
GRCh38: chr11:108317422 G>C
Gene:
ATM
Transcript:
NM_000051.4
Final call
VUS
PP3 supporting
BS3 supporting
Variant details
Gene
ATM
Transcript
NM_000051.4
Protein
NP_000042.3:p.(Gly2083Ala)
gnomAD AF
2.4811094529029602e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PP3 supporting: SpliceAI maximum delta 0.463 meets the ATM VCEP threshold for predicted splice impact.
2
BS3 supporting: direct prime-editing classified c.6248G>C as Functional with High confidence, indicating functional rescue.
Final determination:
Under the ATM VCEP Version 1.6 combining rules, PP3 supporting alone does not satisfy a pathogenic rule and BS3 supporting alone does not satisfy a benign rule; with neither side reaching a rule threshold, the call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.6248G>C is a missense substitution, whereas the VCEP PVS1 rule applies to specified null variants. |
cspec
vcep_atm_pvs1_1_6
|
| PS1 | Not met | Not met: no same-amino-acid pathogenic comparator was identified, and SpliceAI max delta 0.463 does not rule out splicing. |
vcep_atm_ps1_1_6
cspec
PMID:33320972
spliceai
|
| PS2 | N/A | Not applicable: the ATM VCEP specification explicitly marks PS2 as not applicable. |
cspec
|
| PS3 | Not met | Not met: direct prime-editing classified c.6248G>C as Functional with High confidence, indicating rescue rather than failure of ATM-specific function. |
cspec
vcep_suppl_tables1_pmid_40580951
PMID:40580951
vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1
|
| PS4 | Not assessed | Not assessed: available studies report aggregate ATM missense associations, not variant-specific counts or an odds ratio for c.6248G>C. |
cspec
PMID:28779002
PMID:33471991
PMID:24418350
PMID:25394175
PMID:20301317
PMID:20301790
|
| PM1 | N/A | Not applicable: the ATM VCEP prohibits PM1 because benign and pathogenic variants occur in the same domains and hotspots are not well defined. |
cspec
|
| PM2 | Not met | Not met: the highest gnomAD v4.1 subpopulation AF is 0.00160%, above 0.001%, and the variant also occurs in European non-Finnish individuals. |
cspec
gnomad_v4
|
| PM3 | Not assessed | Not assessed: no affected-proband, pathogenic-in-trans, phenotype, or phase evidence was available to assign the ATM VCEP's PM3 points. |
cspec
vcep_atm_pm3_bp2_1_6
|
| PM4 | N/A | Not applicable: p.(Gly2083Ala) is a missense substitution with no stop-loss consequence, the sole variant type allowed by the VCEP PM4 rule. |
cspec
|
| PM5 | N/A | Not applicable: the ATM VCEP explicitly excludes missense changes from PM5, regardless of same-residue comparator evidence. |
cspec
|
| PM6 | N/A | Not applicable: the ATM VCEP specification explicitly marks PM6 as not applicable. |
cspec
|
| PP1 | Not assessed | Not assessed: no documented affected-relative segregation count or informative meioses is available to meet the VCEP's PP1 thresholds. |
cspec
|
| PP2 | N/A | Not applicable: the ATM VCEP states that ATM lacks a defined low rate of benign missense variation. |
cspec
|
| PP3 | Met | Met: SpliceAI max delta 0.463 meets the ATM VCEP PP3 threshold of >=0.2 for predicted splice impact in missense variants. |
cspec
spliceai
revel
vcep_suppl_tables1_pmid_40580951
PMID:40580951
|
| PP4 | N/A | Not applicable: the ATM VCEP excludes PP4 for hereditary breast cancer and directs ataxia-telangiectasia phenotype evidence into PM3/BP2. |
cspec
|
| PP5 | N/A | Not applicable: the ATM VCEP explicitly prohibits use of PP5. |
cspec
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 6.8e-07 (0.000068%), below the VCEP's >0.5% BA1 threshold. |
cspec
gnomad_v4
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 6.8e-07 (0.000068%), below the VCEP's >0.05% BS1 threshold. |
cspec
gnomad_v4
|
| BS2 | N/A | Not applicable: the ATM VCEP excludes BS2 because ATM has incomplete penetrance, regardless of healthy-individual or homozygote observations. |
cspec
|
| BS3 | Met | Met at Supporting: direct prime-editing classified c.6248G>C as Functional with High confidence and DeepATM_predicted=No. |
cspec
vcep_suppl_tables1_pmid_40580951
PMID:40580951
vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1
|
| BS4 | N/A | Not applicable: the ATM VCEP specification explicitly marks BS4 as not applicable. |
cspec
|
| BP1 | N/A | Not applicable: missense pathogenic variants are known for ATM, so the ATM VCEP excludes BP1. |
cspec
|
| BP2 | Not assessed | Not assessed: no unaffected-adult observation, pathogenic co-occurring variant, or cis/trans phase evidence was available to assign the ATM VCEP's BP2 points. |
cspec
vcep_atm_pm3_bp2_1_6
|
| BP3 | N/A | Not applicable: the VCEP marks BP3 not applicable, and this variant is missense rather than an in-frame deletion or insertion. |
cspec
|
| BP4 | Not met | Not met: REVEL 0.295 exceeds the <=0.249 BP4 cutoff and SpliceAI max delta 0.463 exceeds the <=0.1 no-impact cutoff. |
cspec
spliceai
revel
vcep_suppl_tables1_pmid_40580951
PMID:40580951
|
| BP5 | N/A | Not applicable: the ATM VCEP instructs reviewers not to use BP5 because ATM has low penetrance and frequent pathogenic-variant co-occurrence. |
cspec
|
| BP6 | N/A | Not applicable: the ATM VCEP explicitly prohibits use of BP6. |
cspec
|
| BP7 | N/A | Not applicable: BP7 is limited to synonymous or deep intronic variants, but this variant is missense. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.